Literature DB >> 8598867

A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis.

E J Weiss1, P F Bray, M Tayback, S P Schulman, T S Kickler, L C Becker, J L Weiss, G Gerstenblith, P J Goldschmidt-Clermont.   

Abstract

BACKGROUND: Platelet glycoprotein IIb/IIIa is a membrane receptor for fibrinogen and von Willebrand factor, and it has an important role in platelet aggregation. It is known to be involved in the pathogenesis of acute coronary syndromes. Previously, we found a high frequency of a particular polymorphism, PlA2, of the gene encoding glycoprotein IIIa in kindreds with a high prevalence of premature myocardial infarction.
METHODS: To investigate the relation between the PlA2 polymorphism and acute coronary syndromes, we conducted a case-control study of 71 case patients with myocardial infarction or unstable angina and 68 inpatient controls without known heart disease. The groups were matched for age, race, and sex. We used two methods to determine the PlA genotype: reverse dot blot hybridization and allele-specific restriction digestion.
RESULTS: The prevalence of PlA2 was 2.1 times higher among the case patients than among the controls (39.4 percent vs. 19.1 percent, P=0.01). In a subgroup of patients whose disease began before the age of 60 years, the prevalence of PlA2 was 50 percent, a value that was 3.6 times that among control subjects under 60 years of age (13.9 percent, P=0.002). Among subjects with the PlA2 polymorphism, the odds ratio for having a coronary event was 2.8 (95 percent confidence interval, 1.2 to 6.4). In the patients less than 60 years of age at the onset of disease, the odds ratio was 6.2 (95 percent confidence interval, 1.8 to 22.4).
CONCLUSIONS: We observed a strong association between the PlA2 polymorphism of the glycoprotein IIIa gene and acute coronary thrombosis, and this association was strongest in patients who had had coronary events before the age of 60 years.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8598867     DOI: 10.1056/NEJM199604253341703

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  85 in total

1.  A multilocus genotyping assay for candidate markers of cardiovascular disease risk.

Authors:  S Cheng; M A Grow; C Pallaud; W Klitz; H A Erlich; S Visvikis; J J Chen; C R Pullinger; M J Malloy; G Siest; J P Kane
Journal:  Genome Res       Date:  1999-10       Impact factor: 9.043

Review 2.  Platelet PlA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics.

Authors:  P J Goldschmidt-Clermont; C M Roos; G E Cooke
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

3.  The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions.

Authors:  K V Vijayan; P J Goldschmidt-Clermont; C Roos; P F Bray
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

4.  The Pl(A2) allele and cardiovascular disease: the pro(33) and con.

Authors:  T V Byzova; E F Plow
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

Review 5.  The impact of molecular medicine upon early cardiovascular drug development.

Authors:  M W Lunnon; M Braddock
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

6.  Interaction between the platelet IIb/IIIa receptor gene and serotonin transporter gene is involved in the formation of the predisposition to myocardial infarction in young men.

Authors:  D V Demidova; O V Sirotkina; S V Kudinov; E I Schwartz
Journal:  Dokl Biochem Biophys       Date:  2002 Nov-Dec       Impact factor: 0.788

Review 7.  Role of platelet glycoprotein polymorphisms in cardiovascular diseases.

Authors:  Christian Meisel; José A López; Karl Stangl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-12       Impact factor: 3.000

8.  The role of exercise on platelet aggregation in patients with stable coronary artery disease: exercise induces aspirin resistant platelet activation.

Authors:  Burak Pamukcu; Huseyin Oflaz; Rezzan Deniz Acar; Sabahattin Umman; Nevres Koylan; Berrin Umman; Yilmaz Nisanci
Journal:  J Thromb Thrombolysis       Date:  2005-08       Impact factor: 2.300

9.  Antiplatelet drugs: mechanisms and risks of bleeding following cardiac operations.

Authors:  Victor A Ferraris; Suellen P Ferraris; Sibu P Saha
Journal:  Int J Angiol       Date:  2011-03

Review 10.  Integrin αIIbβ3: from discovery to efficacious therapeutic target.

Authors:  Kamila Bledzka; Susan S Smyth; Edward F Plow
Journal:  Circ Res       Date:  2013-04-12       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.